Healthcare / Medical Instruments & SuppliesNasdaqCM
$1.00
-0.03 (-3.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-7.0M · quality 59.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-83.7%
↓Gross Margin
21.3%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+40.1%
FCF CAGR
—
FCF margin
-282.7%
FCF / Net income
0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.7M · net income $-7.6M · FCF $-7.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $2.7M | $2.7M | $1.6M | $1.2M | $659788.00 | $690670.00 |
| Net Income | $-7.6M | $-7.6M | $-7.8M | $-6.7M | $-5.7M | $-3.2M |
| EBITDA | $-8.4M | $-8.4M | $-7.8M | $-6.6M | $-5.5M | — |
| EPS | — | — | -5.19 | -10.87 | -17.40 | — |
| Gross Margin | 21.3% | 21.3% | 13.1% | -10.4% | -8.5% | 21.5% |
| Operating Margin | -319.2% | -319.2% | -484.2% | -594.9% | -845.2% | — |
| Net Margin | -285.2% | -285.2% | -474.6% | -578.2% | -861.2% | -469.8% |
| Balance Sheet | ||||||
| Debt/Equity | — | — | — | — | 0.02 | — |
| Current Ratio | 8.02 | 8.02 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-7.5M | $-7.5M | $-7.0M | $-6.0M | $-3.4M | $-1.2M |
| Returns | ||||||
| ROE | -83.7% | -83.7% | -85.4% | -119.9% | -141.2% | -1563.5% |
| Valuation | ||||||
| P/B | 0.61 | 0.61 | 0.91 | 0.92 | 2.01 | — |
| Growth & Yield | ||||||
| Revenue Growth | 62.6% | 62.6% | 42.0% | 74.7% | — | — |
| EPS Growth | — | — | 52.3% | 37.5% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-68.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.19 → n/d
Residual
-68.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.